EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glypican-3-Specific CAR NK Cells Co-Secreting IL-15 and IFN-α Have Increased Anti-Tumor Function Versus Hepatocellular Carcinoma In Vitro

Rosalia Busà iD, Gioacchin Iannolo iD, Bruno Douradinha iD, Duilio Pagano iD, Anna Gallina, Giancarlo Cappello, Antonio La Rocca, Salvatore Gruttadauria iD, Pier Giulio Conaldi iD, Ester Badami iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262411892 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Rosalia Busà und 9 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS ISMETT, 90127 Palermo, Italy. Hauptthemen laut MEDLINE: Interleukin-15, Carcinoma, Hepatocellular, Glypicans, Liver Neoplasms. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Ri.MED (Fondo Generale, ID 10019) and IRCCS-ISMETT ATMP-P A105412 project, The Italian Ministry of Health, Fondazione Ri.MED.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-modified natural killer (NK) cells represent a promising immunotherapeutic approach for the treatment of oncological malignancies such as hepatocellular carcinoma (HCC). In this work, we have engineered primary human NK cells, re-directing them so they can specifically recognize Glypican-3 (GPC3), an immunotherapeutic target for HCC. In previous studies, we have demonstrated that IFN-α significantly enhances NK cells’ anti-tumor and anti-viral cytotoxicity. Fourth-generation self-inactivating lentiviral vectors were used to deliver a transgenic expression of IFN-α or its co-expression with IL-15 (which induces NK cells expansion, survival, and function), aiming to enhance CAR-GPC3 NK cells’ anti-tumor response against HCC. We optimized a protocol for efficient transduction of primary NK cells, demonstrating that CAR expression is maintained at high levels over time. Exposure of HCC ectopically expressing GPC3+ to CAR-GPC3-IL15 and CAR-GPC3-IL15-IFNα NK cells demonstrated significant in vitro cytotoxicity and cytokine production, dependent on GPC3 expression. To prevent undesired side effects of CAR-NK cell immunotherapy, co-delivery with a suicide gene is advised as a safety measure. Thus, a truncated epidermal growth factor receptor (tEGFR) was co-delivered with the anti-GPC3 CAR, which efficiently promoted the suicide of the CAR-NK used in this work. Our study demonstrates the efficacy of re-directed CAR-GPC3 primary NK cells, encouraging further preclinical and clinical translation studies and strengthening the potential of these cells as a novel treatment option for patients with HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-15Carcinoma, HepatocellularGlypicansLiver NeoplasmsKiller Cells, NaturalInterferon-alphaReceptors, Chimeric AntigenHumansCell Line, TumorImmunotherapy, Adoptive

Stichwörter der Autor:innen

Glypican-3adoptive cell therapycancer immunotherapychimeric antigen receptorgenetic modificationhepatocellular carcinomanatural killer cells

Substanzen

Interleukin-15GlypicansInterferon-alphaReceptors, Chimeric AntigenGPC3 protein, humanIL15 protein, human

Autor:innen und Institutionen

  • IRCCS ISMETT, 90127 Palermo, Italy.
  • Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy.
  • Fondazione Ri.MED, 90133 Palermo, Italy.
  • Department of Surgery and Medical and Surgical Specialties, University of Catania, 95124 Catania, Italy.

ORCID-Profile: Rosalia Busà, Gioacchin Iannolo, Bruno Douradinha, Duilio Pagano, Salvatore Gruttadauria, Pier Giulio Conaldi, Ester Badami

Förderung

  • Fondazione Ri.MED (Fondo Generale, ID 10019) and IRCCS-ISMETT ATMP-P A105412 project
  • The Italian Ministry of Health
  • Fondazione Ri.MED
  • ISMETT
  • Italian Ministry of Health, Ricerca Corrente

Zitieren

APA

Busà, R., Iannolo, G., Douradinha, B., Pagano, D., Gallina, A., Cappello, G., La Rocca, A., Gruttadauria, S., Conaldi, P. G., & Badami, E. (2025). Glypican-3-Specific CAR NK Cells Co-Secreting IL-15 and IFN-α Have Increased Anti-Tumor Function Versus Hepatocellular Carcinoma In Vitro. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262411892

Vancouver

Busà R, Iannolo G, Douradinha B, Pagano D, Gallina A, Cappello G, et al. Glypican-3-Specific CAR NK Cells Co-Secreting IL-15 and IFN-α Have Increased Anti-Tumor Function Versus Hepatocellular Carcinoma In Vitro. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262411892

BibTeX
@article{Bus2025,
  author = {Busà, Rosalia and Iannolo, Gioacchin and Douradinha, Bruno and Pagano, Duilio and Gallina, Anna and Cappello, Giancarlo and La Rocca, Antonio and Gruttadauria, Salvatore and Conaldi, Pier Giulio and Badami, Ester},
  title = {Glypican-3-Specific CAR NK Cells Co-Secreting IL-15 and IFN-α Have Increased Anti-Tumor Function Versus Hepatocellular Carcinoma In Vitro},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262411892}
}
Kostenlos starten →